摘要
目的观察莫西沙星治疗恶性肿瘤合并医院获得性肺炎(HAP)的临床效果和安全性。方法 102例恶性肿瘤合并HAP病例,随机分为治疗组52例、对照组50例;治疗组应用莫西沙星治疗,对照组应用左氧氟沙星治疗,观察其临床效果和安全性。结果治疗组及对照组总有效率分别是80.8%和58.0%,痊愈率分别为50.0%和32.0%,两组共分离出细菌121株,细菌清除率分别为80.3%和58.3%、不良反应发生率分别为3.9%和10.0%,差异均有统计学意义(P<0.05)。结论莫西沙星治疗恶性肿瘤合并HAP患者临床疗效较好,细菌清除率高、优于左氧氟沙星,临床使用安全。
OBJECTIVE To observe the clinical efficacy and safety of moxifloxacin in treatment of malignant tumor merged hospital acquired character pneumonia. METHODS A total of 102 example malignant tumor complicated with HAP were divided into the treatment group（52 examples） and the control group（50 examples） radomly.The treatment group applied moxifloxacin star treatment,the control group applied levofloxacin to treat,its clinical effect and the security were observed. RESULTS Two groups of total effectiveness respectively were 80.8% and 58.0%,the healing rates respectively were 50.0% and 32.0%,two groups altogether separates bacterium 121,the bacterium percentage clearance respectively were 80.3% and 58.3%（P〈0.05）.The untoward effect formation rate respectively were 3.9% and 10.0%（P〈0.05）. CONCLUSION Moxifloxacin applied for the treatment of malignant tumor merged HAP has a good clinical effect and is with a high bacterial clearance rate,which is superior to levofloxacin and safe for the clinical use.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2011年第22期4794-4796,共3页
Chinese Journal of Nosocomiology
基金
浙江省医学会临床科研基金项目(2008CYC56)
